'Go quickly': Amgen R&D vet Dirk Nagorsen jumps to a startup with big plans for TCRs
You can call it the summer of inception at Affini-T Therapeutics, the TCR upstart out of the Fred Hutch.
Born with a trio of distinguished scientific godfathers, including Phil Greenberg. Backed by a pair of deep-pocket investors at Vida Ventures and Leaps by Bayer, won over by Affini-T’s swing-for-the-bleachers style. It’s even already done a high-profile collaboration with a new gene-editing biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.